Alcohol overuse disrupts liver function and alters gut microbial communities, with alcohol-related liver disease (ALD) causing half of all liver-relat…

Semaglutide showed robust therapeutic effects in treatment-seeking participants with obesity and alcohol use disorder and this trial supports previous preclinical and clinical findings suggesting GLP-...

Phosphatidylethanol is a direct biomarker of alcohol consumption within the past 1–4 weeks, making it a potential tool in the subclassification of pat…

Steatotic liver disease often progresses asymptomatically, with the risk of advancing to cirrhosis and liver cancer. Early detection of advanced liver disease through screening presents an opportunity...

Phosphatidylethanol (PEth) is an ethanol metabolite used as a specific biomarker for recent alcohol consumption. We aimed to determine the proportion …

Steatotic liver disease (SLD) includes the subclasses metabolic-dysfunction associated steatotic liver disease (MASLD), metabolic and alcohol-related liver disease (MetALD) and alcohol-related liver d...

Portal hypertension (PH) leads to life-threatening clinical manifestations such as bleeding from gastro-oesophageal varices, ascites and its complications, and portosystemic encephalopathy. It can dev...

Cirrhosis incidence due to alcohol-related liver disease (ALD) is decreasing in Denmark, while the obesity incidence is increasing, expectably driving…

For several decades, the prevalence of steatotic liver disease (SLD) has been steadily increasing.1 Alterations in hepatic lipid metabolism, causing steatosis, can result from several factors predomin...